Jazz Pharmaceuticals PLC

JAZZ: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
d!<LOCK|hnLOCK|gFJ^%P

Jazz: Ziihera's Positive Survival Data Supports Growth Beyond Core Sleep Franchise

Jazz presented analysis from its study of Ziihera in HER2-positive advanced gastroesophageal adenocarcinoma, demonstrating sustained survival benefit at three years. Ziihera plus tislelizumab and chemotherapy showed an improved overall survival hazard ratio of 0.65.

Sponsor Center